Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Further Reading

Compugen, Bayer sign collaboration and license agreement for antibody-based cancer immunotherapies

Compugen, Bayer sign collaboration and license agreement for antibody-based cancer immunotherapies

5 Aug 2013
Research aims to provide physicians a more targeted approach to treating ER+ breast cancer

Research aims to provide physicians a more targeted approach to treating ER+ breast cancer

2 Aug 2013
AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

31 Jul 2013
FibroGen, Astellas initiate Phase 2 study of ASP1517/FG-4592 for treatment of anemia linked with CKD

FibroGen, Astellas initiate Phase 2 study of ASP1517/FG-4592 for treatment of anemia linked with CKD

31 Jul 2013
NIAID researchers discover monoclonal antibody can neutralize human norovirus

NIAID researchers discover monoclonal antibody can neutralize human norovirus

25 Jul 2013
FDA grants orphan drug designation to ARMAGEN's AGT-182 for treatment of Hunter syndrome

FDA grants orphan drug designation to ARMAGEN's AGT-182 for treatment of Hunter syndrome

19 Jul 2013
FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

19 Jul 2013
Ablynx initiates additional Phase I studies with anti-RSV Nanobody ALX-0171

Ablynx initiates additional Phase I studies with anti-RSV Nanobody ALX-0171

18 Jul 2013
AbGenomics raises $9.6M for advancing therapeutic antibodies for autoimmune diseases, cancers

AbGenomics raises $9.6M for advancing therapeutic antibodies for autoimmune diseases, cancers

18 Jul 2013
Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

17 Jul 2013
Qualigen's FastPack Vitamin D Immunoassay receives FDA clearance

Qualigen's FastPack Vitamin D Immunoassay receives FDA clearance

16 Jul 2013
Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

15 Jul 2013
ADC Therapeutics, BZL Biologics sign licensing deal for antibody against PSMA-positive prostate cancers

ADC Therapeutics, BZL Biologics sign licensing deal for antibody against PSMA-positive prostate cancers

15 Jul 2013
Antibodies boost immune system to fight childhood cancer, shows study

Antibodies boost immune system to fight childhood cancer, shows study

12 Jul 2013
Protein that triggers blood clotting plays critical role in growth of pancreatic and breast cancer

Protein that triggers blood clotting plays critical role in growth of pancreatic and breast cancer

12 Jul 2013
Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

9 Jul 2013
Cancer immunotherapies promise to be a new tool in fight against cancer

Cancer immunotherapies promise to be a new tool in fight against cancer

9 Jul 2013
MerTK inhibition in leukocytes decreases tumor growth and metastasiss

MerTK inhibition in leukocytes decreases tumor growth and metastasiss

9 Jul 2013
ALK immunocytochemistry accurately detects NSCLC on cytological specimens

ALK immunocytochemistry accurately detects NSCLC on cytological specimens

2 Jul 2013
Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

1 Jul 2013

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback